In 2026, the study published in *Biomedicines 2026* reviewed inflammation in patients with chronic kidney disease. The meta-analysis cited found a significant reduction in CRP with fish oil, whilst IL-6 and TNF-α showed inconsistent results. The findings support the use of CRP as a marker for monitoring the inflammatory response in this population.
The evidence relates to people with chronic kidney disease, including those on haemodialysis. The trials varied in terms of dosage, duration and outcomes. The review calls for well-designed prospective studies to validate clinical applications.
Persistent inflammation links kidney damage to cardiovascular risk
In chronic kidney disease, low-grade inflammation increases as kidney function declines. Uraemia, oxidative stress and inadequate clearance of mediators sustain this immune activity.
This environment promotes tubulointerstitial fibrosis, a poorer prognosis and increased cardiovascular risk. Lipid and mitochondrial abnormalities exacerbate oxidative damage and immune activation.
EPA and DHA generate mediators that promote inflammatory resolution
Specialised pro-resolving mediators are derived from polyunsaturated fatty acids. EPA gives rise to E-series resolvins. DHA generates D-series resolvins, protectins and maresins.
These mediators limit the recruitment of neutrophils and promote the clearance of cellular debris. They also steer macrophages towards a reparative profile.
The mechanisms involved include reduced NF-κB signalling and lower production of inflammatory cytokines. Nrf2, PPAR-γ and the regulation of reactive oxygen species are also involved.
The nephroprotective and antifibrotic effects are primarily derived from experimental renal models. Their clinical application requires prospective validation.
Clinical studies show significant changes with mixed results
A 12-week randomised trial found significant reductions in IL-6, CRP and TNF-α in patients on haemodialysis.
Another six-month trial improved glutathione peroxidase activity and reduced CRP. It also recorded a favourable modulation of lipid metabolism.
A 2024 meta-analysis pooled the results of thirteen randomised trials. Fish oil significantly reduced CRP, with a p-value of 0.01.
Changes in IL-6 and TNF-α remained inconsistent. Some trials significantly reduced triglycerides, whilst others found no significant changes in lipid levels.
The observational association with DHA remains specific in scope
One cohort exceeded 80,000 participants and included 6,735 people with chronic kidney disease. The median follow-up was 11.9 years.
Among those with chronic kidney disease, higher levels of circulating DHA were associated with a lower risk of renal replacement therapy.
This finding is observational and retains a risk of residual confounding. The association does not establish causality nor define a therapeutic dose.
Nutribiolite DHA-PS provides the omega-3s mentioned in the review
The review analyses EPA and DHA, the same omega-3s found in the fish oil in DHA-PS. This overlap provides the main scientific link.
DHA-PS contains Omegatex® oil with 50 per cent DHA and 10 per cent EPA. The DHA is present in the form of highly bioavailable triglycerides.
Each daily dose provides 500 mg of DHA. DHA contributes to normal brain function and the maintenance of normal vision.
The authorised health claim is based on a daily intake of 250 mg of DHA. The formula also provides 100 mg of phosphatidylserine per day.
Sharp-PS® Green is derived from European sunflower lecithin and is soya-free. Its purity and bioavailability underpin its technical selection.
The lipid medium provided by the oil facilitates the solubilisation and intestinal absorption of phosphatidylserine. This combination results in a specific and convenient formula.
DHA-PS combines the DHA and EPA studied in the review with sunflower phosphatidylserine within a specific lipid-based formula.
Five answers clarify the evidence and use of DHA-PS
What was the main finding of the review?
The meta-analysis cited found a significant reduction in CRP with fish oil. Changes in IL-6 and TNF-α were inconsistent.
Which population was covered by the reviewed evidence?
The clinical evidence related to patients with chronic kidney disease, including those on haemodialysis and those with end-stage renal disease.
How do EPA and DHA contribute to the resolution of inflammation?
EPA and DHA give rise to resolvins, protectins and maresins. These mediators regulate neutrophils, macrophages, cytokines and oxidative stress.
What is the link between DHA-PS and the study?
DHA-PS contains DHA and EPA, the omega-3 fatty acids examined in the review. Its clinical results cannot be attributed to the product.
How should DHA-PS be taken and what precautions should be taken?
Take one capsule twice a day with a meal. Do not exceed the recommended dose. Medical advice is required during pregnancy and whilst breastfeeding.
This content is for information purposes only and is not a substitute for advice from a healthcare professional.
